BCL2 and B-cell chronic lymphocytic leukemia: Navitoclax has had promising response rates in clinical trials in chronic lymphocytic leukaemia (CLL), a cancer type highly dependent upon Bcl-2 pathways for survival, but with high levels of toxicity: severe thrombocytopenia in one-third of patients.